antibacterial soaps may be hazardous to your health


there was an important editorial in the NY Times today on governmental ineffectiveness in regulating industrial chemicals (see http://www.nytimes.com/2014/11/10/opinion/making-chemistry-green.html?emc=edit_th_20141110&nl=todaysheadlines&nlid=67866768&_r=0). the potential effects are profound and not significantly different from data i saw in the early 1970s.

--there are 84,000 chemical compounds in commercial use, with 500-1000 new ones introduced annually
--in an analysis of 143,000 peer-reviewed research papers, it takes an average of 14 years from the time safety issues are raised and action taken (while the chemicals remain in the market)
--the case in point in the article is the use of triclosan and triclocarban, ubiquitous environmental contaminants used in anti-bacterial soaps, cosmetics and other consumer products for the past 40 years.
--these chemicals are from the same class as "persistent, bioaccumulative and toxic compounds known as organohalogens", such as DDT, and are known to interfere with the human endocrine system and may be related to the development of bacterial resistance
--dozens of organohalogens have been detected mothers and babies, with altered hormone levels, lower birth weights, reduced head circumferences
--and, to boot, the addition of these antibacterials is no better than using regular soap: the CDC has published: "Researchers found that incidence of disease did not differ significantly between households given plain soap versus antibacterial soap" (http://www.cdc.gov/media/pressrel/r050714a.htm).

so, my recollection from the 1970s (when regulation was probably more robust than today) was that the government was able to do a thorough review of about 5 new industrial chemicals/year through NIOSH (the research arm of OSHA), which was dwarfed by the large number of new chemicals introduced annually into industry and the environment. my concern is obvious (and iterated repeatedly in prior blogs): we are seeing lots of potential long-term consequences of carcinogens, for example, yet so much of our approach is early detection (mammography has marginal benefit in preventing breast cancer deaths, though 12% of all US women develop invasive breast cancer. colonoscopy is probably more effective than mammography, yet the number of untested food additives is shocking)....

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

cystatin c: better predictor of bad outcomes than creatinine

  another article found significant discordance between creatinine and cystatin C in assessing renal function,  finding that the latter correlated most strongly with both renal and non-renal adverse clinical outcomes (see   ckd cystatin c better than creat AJKD2023  in  dropbox or doi: 10.1053/ j.ajkd.2023.04.002)   Details: -- 158,601 adults who were in the Stockholm Creatinine Measurements (SCREAM) project and had testing of creatinine and cystatin C on the same day during a healthcare encounter, from 2010-2018     -- >400,000 outpatient tests were done for both creatinine and cystatin C levels -- mean age 62, 48% female -- mean eGFR by creatinine (   eGFR cr ) 80; mean eGFR by cystatin C ( eGFR cys  ) 73 -- mean stage of renal insufficiency: 39%  eGFR cr   90+; 38%  eGFR cr  60-89; 12%  eGFR cr  45-59; 7.1%  eGFR cr  30-44; 3.2%  eGFR cr  15-29, 0.7%  eGFR cr ...
Read more

diabetes DPP-4 inhibitors and the risk of heart failure

the FDA just came out with a safety alert about 2 DPP-4 inhibitors and the increased risk of heart failure (released 04/05/2016)(see  http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery ​ ). details: --saxagliptin and alogliptin were singled out because of 2 clinical trials in diabetic patients with heart disease. in each trial more patients taking these meds were hospitalized for heart failure vs those on placebo     --in the saxagliptin trial: 3.5% were hospitalized for heart failure (vs 2.8% on placebo). risk factors included prior heart failure or kidney disease     --in the alogliptin trial: 3.9% were hospitalized for heart failure (vs 3.3% on placebo) --recommendation by the FDA:     -- we should consider stopping these drugs if the patient develops heart failure ...
Read more

UPDATE: ASCVD risk factor critique

I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the current ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:          ...
Read more